0001104659-22-069531.txt : 20220609 0001104659-22-069531.hdr.sgml : 20220609 20220609090049 ACCESSION NUMBER: 0001104659-22-069531 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220609 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220609 DATE AS OF CHANGE: 20220609 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZYNEX INC CENTRAL INDEX KEY: 0000846475 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 870403828 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38804 FILM NUMBER: 221005038 BUSINESS ADDRESS: STREET 1: 9655 MAROON CIRCLE CITY: ENGLEWOOD STATE: CO ZIP: 80112 BUSINESS PHONE: (800)-495-6670 MAIL ADDRESS: STREET 1: 9655 MAROON CIRCLE CITY: ENGLEWOOD STATE: CO ZIP: 80112 FORMER COMPANY: FORMER CONFORMED NAME: ZYNEX MEDICAL HOLDINGS INC DATE OF NAME CHANGE: 20050812 FORMER COMPANY: FORMER CONFORMED NAME: ZYNEX MEDICAL HOLDINGS INC DATE OF NAME CHANGE: 20040120 FORMER COMPANY: FORMER CONFORMED NAME: FOX RIVER HOLDINGS INC DATE OF NAME CHANGE: 20031126 8-K 1 tm2218016d1_8k.htm FORM 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 9, 2022

Zynex, Inc.

(Exact Name of Registrant as Specified in its Charter)

Nevada

001-38804

90-0275169

(State or other jurisdiction
of incorporation)

Commission File
Number

(I.R.S. Employer Identification

number)

9655 Maroon Circle, Englewood, CO 80112

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (800) 495-6670

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Ticker symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	ZYXI	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

ITEM 8.01 OTHER EVENTS

On June 9, 2022, the Company issued a press release announcing that its Board of Directors authorized a share buyback program for up to $10.0 million of the Company’s common stock.

Under the share buyback program, buybacks may be made from time-to-time in open market and negotiated purchases, effective immediately through the next twelve months. These buybacks will be made in compliance with the SEC's Rule 10b-18, subject to market conditions, available liquidity, cash flow, applicable legal requirements and other factors. This program does not obligate the Company to acquire any particular amount of common stock and the program may be suspended or discontinued at any time. The Company expects to finance the purchases with existing cash balances.

The full text of the press release is furnished herewith as Exhibit 99.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

d) Exhibits. The following exhibits are filed with this report.

Exhibit No.	Description
99.1	Zynex, Inc. Press Release dated June 9, 2022

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: June 9, 2022	ZYNEX, INC.

	/s/ Dan Moorhead
	Dan Moorhead
	Chief Financial Officer

EX-99.1 2 tm2218016d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Zynex Announces Additional Share Buyback Program

Englewood, CO – June 9, 2022 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to buy back $10.0 million of the Company's common stock. The program will commence on June 10, 2022 and is scheduled to terminate on June 9, 2023 or when the $10.0 million buyback limit is reached.

In making the announcement, Zynex CEO Thomas Sandgaard stated, "We fully utilized the $10 million buyback we announced in April, completing all purchases in less than fifty days. The additional $10 million share buyback reiterates our continued commitment to delivering shareholder value and reflects the board's confidence in our short-term prospects and our long-term growth strategy. In addition, we believe the current market value of our shares does not accurately reflect the Company's underlying value, and the buyback program represents an attractive opportunity to deploy capital in a way that will benefit stockholders."

Under the share buyback program, buybacks may be made from time-to-time in open market and negotiated purchases, effective immediately through the next twelve months. These buybacks will be made in compliance with the SEC's Rule 10b-18, subject to market conditions, available liquidity, cash flow, applicable legal requirements, and other factors. The specific prices, numbers of shares, and timing of purchase transactions will be determined by the Company from time to time in its sole discretion. This program does not obligate the Company to acquire any particular amount of common stock, and the program may be suspended or discontinued at any time, including in the event the Company would be deemed to be making an acquisition of its own shares under Rule 13e-3 of the Securities Exchange Act of 1934, as amended.

The Company expects to finance the purchases with existing cash balances, which is not expected to have a material impact on capital levels.

Zynex, Inc. had approximately 41.6 million shares issued and 38.5 million shares outstanding as of June 8, 2022.

About Zynex, Inc.

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore you should not rely on any of these forward looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our products on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2021 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.

Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact: Zynex, Inc. (800) 495-6670

Investor Relations Contact:
Gilmartin Group

650 Fifth Ave., Suite 2720

New York, NY 10019
ir@zynex.com

EX-101.SCH 3 zyxi-20220609.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 zyxi-20220609_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 zyxi-20220609_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Jun. 09, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jun. 09, 2022
Entity File Number	001-38804
Entity Registrant Name	Zynex, Inc.
Entity Central Index Key	0000846475
Entity Tax Identification Number	90-0275169
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	9655 Maroon Circle
Entity Address, City or Town	Englewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80112
City Area Code	800
Local Phone Number	495-6670
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	ZYXI
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 7 tm2218016d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000846475 2022-06-09 2022-06-09 iso4217:USD shares iso4217:USD shares 0000846475 false 8-K 2022-06-09 Zynex, Inc. NV 001-38804 90-0275169 9655 Maroon Circle Englewood CO 80112 800 495-6670 false false false false Common Stock, $0.001 par value per share ZYXI NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://zynexmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2218016d1_8k.htm tm2218016d1_ex99-1.htm zyxi-20220609.xsd zyxi-20220609_lab.xml zyxi-20220609_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2218016d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2218016d1_8k.htm" ] }, "labelLink": { "local": [ "zyxi-20220609_lab.xml" ] }, "presentationLink": { "local": [ "zyxi-20220609_pre.xml" ] }, "schema": { "local": [ "zyxi-20220609.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "zyxi", "nsuri": "http://zynexmed.com/20220609", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2218016d1_8k.htm", "contextRef": "From2022-06-09to2022-06-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://zynexmed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2218016d1_8k.htm", "contextRef": "From2022-06-09to2022-06-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001104659-22-069531-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-069531-xbrl.zip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�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end